Alnylam Pharma (ALNY – Research Report) received a Hold rating and price target from Goldman Sachs analyst Salveen Richter today. The company’s shares closed today at $147.43.
According to TipRanks, Richter is a 5-star analyst with an average return of 16.4% and a 45.61% success rate. Richter covers the Healthcare sector, focusing on stocks such as Biogen, Vertex Pharmaceuticals, and Amgen.
In addition to Goldman Sachs, Alnylam Pharma also received a Hold from Morgan Stanley’s Michael Ulz in a report issued on February 13. However, today, Needham maintained a Buy rating on Alnylam Pharma (NASDAQ: ALNY).
See Insiders’ Hot Stocks on TipRanks >>
Based on Alnylam Pharma’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $750.53 million and a net profit of $147.75 million. In comparison, last year the company earned a revenue of $264.31 million and had a GAAP net loss of $405.92 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alnylam Pharma (ALNY) Company Description:
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
Read More on ALNY:
